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Effect of a1-Adrenergic Antagonists on Lower
Ureteral Stones With Extracorporeal Shock 
Wave Lithotripsy
Huijun Wang, Ke Liu, Zhigang Ji and Hanzhong Li, Department of Urology, Chinese Academy of 
Medical Sciences and Peking Union Medical College, Beijing, China.
OBJECTIVE: To evaluate the efficiency of α1-adrenergic antagonists on stone clearance after extracor-
poreal shock wave lithotripsy (ESWL) in patients with lower ureteral stones.
METHODS: A total of 107 patients with solitary lower ureteral stones and who underwent single ESWL
sessions were divided into two groups. Group 1 received our standard medical therapy, and group 2 was
treated with 0.4 mg/day tamsulosin for a maximum of 2 weeks. All patients were re-evaluated with plain
film radiography and ultrasound each week during treatment.
RESULTS: Twenty-four of the 52 patients in group 1 (46.2%) and 41 of 55 patients in group 2 (74.5%)
(p = 0.002) were found to be stone-free. Among patients with stones 10–15 mm in diameter, the stone-free
rate was 36.4% in group 1 and 73.0% in group 2 (p = 0.003). Average stone expulsion time was 11.6 days
and 8.1 days in groups 1 and 2, respectively (p = 0.000). Ureteral colic occurred in 10 patients (19.2%) in
group 1 but only 3 patients (5.5%) in group 2 (p = 0.043). The only side effect of tamsulosin was slight
dizziness in 2 of the 55 (3.6%) patients in group 2.
CONCLUSION: Adjunctive therapy with α1-adrenergic antagonists after ESWL is more effective than,
and equally as safe as lithotripsy alone in the treatment of patients with lower ureteral stones. The use of
α1-adrenergic antagonists is more useful for stones with a large dimension, and can also reduce stone
expulsion time and episodes of ureteral colic. [Asian J Surg 2010;33(1):37–41]
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Introduction
Symptomatic ureteral stone disease is one of the im-
portant issues that urologists face in emergency clinical
settings. Although extracorporeal shock wave lithotripsy
(ESWL) is accepted in many institutions as the first-line
treatment option for patients with ureteral stones, this
approach does not seem to work efficiently when the
stone size increases. Recently, however, ESWL have been
reconsidered for the treatment of larger ureteral stones.
Some authors1,2 have reported positive results in acceler-
ating lower ureteral stone passage using α1-adrenergic
antagonists, on the basis that α1-adrenergic receptors
play an important physiological role in lower ureteral
excretion.3 Here, we perform a comparative study to eval-
uate the safety and effectiveness of α1-adrenergic antago-
nists for the treatment of lower ureteral stones.
Material and methods
Patients
Between January 2005 and June 2008, 110 patients who
had lower ureteral stones were evaluated by physical exam-
ination, serum creatinine measurement, plain abdominal
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X-rays, intravenous pyelography and abdominal B-mode
ultrasound. Patients were excluded from the study if they
had any of the following: urinary tract infection, multiple
stones, severe hydronephrosis, solitary kidney, congenital
urinary anomalies, or previous ureteral surgery. Patients
with severe obesity, pregnancy, lactation, or previous
treatment with α1-adrenergic antagonists were also
excluded. A total of 107 patients met these requirements
and were enrolled in the study.
Treatment
Patients were treated using an HB-ESWL-V (Zhanjiang,
Jiangsu, China) lithotripter. The number of shocks given
to each patient was decided empirically according to the
diameter of the stone. Patients were in the supine position
and no analgesics were used during ESWL. After ESWL,
the patients were assigned to two groups by simple ran-
dom allocation, and placebo-controlled medical treat-
ment was initiated immediately and continued for a
maximum of 2 weeks, or until an alternative treatment
was applied. Standard treatment of 25 mg indomethacin
and 5 g paishi granules (Chinese herbal medicine) was
given three times daily to group 1, the control group.
Group 2 received the standard medical treatment in addi-
tion to 0.4 mg tamsulosin (α1-adrenergic antagonist)
once daily. Furthermore, all patients were instructed to
drink a minimum of 2 L of water daily and were asked to
keep a diary about ureteral colic, stone expulsion and side
effects of medical therapy. Follow-up included clinical
examination, abdominal B-mode ultrasound and/
or intravenous pyelography repeated every week after
lithotripsy.
Statistical analysis
Data were analysed using SPSS 13.0 software (SPSS Inc.,
Chicago, IL, USA).
Results
Patient characteristics are summarized in Table 1. Group 1
consisted of 14 women and 38 men, with a mean age of
40.9 ± 10.3 years (range: 19–62), whereas group 2 consisted
of 19 women and 36 men, with a mean age of 42.2 ± 12.6
years (range: 21–69). Stone diameter was 8.6 ± 3.0 and
9.3 ± 2.6 mm for groups 1 and 2, respectively. The groups
were not significantly different in their demographic and
clinical characteristics (p > 0.05).
All patients underwent one session of ESWL. A mean of
2955.8 ± 256.1 shocks per patient in group 1 was delivered
at a mean voltage of 7.7 ± 0.6 kV, and a mean of 2902.0 ±
241.8 shocks per patient in group 2 was delivered at a
mean voltage of 7.9 ± 0.8 kV, with no significant differ-
ence between the groups (p > 0.05). Twenty-four of the 52
patients in group 1 (46.2%) and 41 of the 55 patients in
group 2 (74.5%) were found to be stone free. The difference
between groups was statistically significant (p = 0.002;
Figure 1A). Among patients with stones 10–15 mm in
diameter, we found a significant difference in the stone-
free rate between the two groups (36.4% in group 1 and
73.0% in group 2; p = 0.003; Figure 1B). In contrast, we
found no significant difference in stone-free rate among
patients with stones 5–9 mm in diameter (63.2% in group
1 and 77.8% in group 2; p = 0.345; Figure 1B). Average stone
expulsion time for groups 1 and 2 was 11.6 ± 1.4 days and
8.1 ± 1.6 days, respectively (p < 0.001). Ureteral colic
occurred in 19.2% of patients in group 1 but in only 5.5%
of patients in group 2 (p = 0.043; Figure 1C).
The only side effect of tamsulosin was slight dizziness
in two of 55 patients in group 2 (3.6%).
Discussion
Urinary stone disease is a significant worldwide health
problem. Of all urinary tract stones, 20% are ureteral, and
70% of these are located in the distal portion of the ureter.
If the diameter of a ureteral stone is less than 4 mm, spon-
taneous passage is generally possible. Ureteral stones
greater than 6 mm in diameter have a ≤ 5% chance of
spontaneous passage.4,5
Currently, ESWL represents the first-line therapeutic
option for lower ureteral stones, but it implies a certain
percentage of re-treatments. The major goal in treating
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Table 1. Demographic and clinical characteristics of patients
Group 1 Group 2
(n= 52) (n= 55)
Mean age (yr) 40.9 ± 10.3 42.2 ± 12.6
Mean weight (kg) 72.4 ± 6.2 73.2 ± 6.1
Stone diameter
5–9 mm 19 18
10–15 mm 33 37
Mean diameter (mm) 8.6 ± 3.0 9.3 ± 2.6
patients with lower ureteral stones is achieving a stone-
free state. Stone fragment expulsion after ESWL is proba-
bly not dissimilar to spontaneous passage. Several
variables play a fundamental role in the migration of cal-
culi: stone size, intrinsic areas of narrowing within the
ureter, ureteral peristalsis, hydrostatic pressure of the col-
umn of urine proximal to the stone and oedema, urinary
tract infection, and spasm of the ureteral site in which the
stone is lodged.6,7
Oedema, urinary tract infection, spasm and ureteral
peristalsis can be modified by appropriate medical ther-
apy. If the friction between the intraureteral wall and the
stone decreases, ureteral relaxation occurs and promotes
stone passage at the site of obstruction. Two factors that
appear to be most useful in facilitating stone passage are
increase in hydrostatic pressure proximal to the stone,
and relaxation of the ureter in the region of the stone. The
primary functional anatomical unit of the ureter is the
ureteral smooth muscle cell.4
The sympathetic nervous system appears to modulate
ureteral activity as shown by the presence of adrenergic
receptors in the ureter. Hancock8 has reported the pres-
ence of α- and β-adrenergic receptors in the human
ureter. Several studies have shown that the density of 
α1-adrenergic receptors in the ureteral smooth muscle
cells is greater than that of other adrenergic receptors.9
According to the general consensus, α-adrenergic re-
ceptor agonists tend to stimulate ureteral activity. β-
Adrenergic receptor agonists tend to inhibit ureteral
activity. α-Adrenergic receptors are found in trigone, pro-
static urethra and ureters. These receptors cause contrac-
tion of the smooth muscles in these regions.10 It is
suggested that α-adrenergic stimulation reduces the vol-
ume of urine flow through the ureter and causes ureteral
spasm.
In contrast, α-adrenergic antagonists can decrease
ureteral peristaltic frequency, which reduces ureteral
spasm. These changes are accompanied by an increase in
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Figure 1. Comparison of stone-free rate between groups 1 (con-
trol) and 2 (tamsulosin). (A) Percentage of patients found to 
be stone free in groups 1 and 2 (p = 0.002). (B) Percentage of
patients found to be stone free in groups 1 and 2 with stone
diameter of 5–9 mm (p = 0.345) and 10–15 mm (p < 0.003). (C)
Percentage of patients with episodes of ureteral colic (p< 0.001).
the rate of fluid transport.1 Based on the evidence that 
α-adrenergic antagonists have an important physiologi-
cal role in lower ureteral excretion, some researchers have
more recently proposed the use of α1-adrenergic antago-
nists for facilitating lower ureteral stone expulsion.11 Sofa
et al12 have reported the spontaneous passage of lower
ureteral stones in 86.6% of patients who were treated with
an α1-adrenergic antagonist, and a significant difference
in the stone-free rate between patients treated with tam-
sulosin and the control group. Koppel et al13 have re-
ported favourable impact of 15-day tamsulosin treatment
on the clearance of residual fragments after ESWL.
Porpiglia et al14 have also shown that the stone-free rate
was significantly greater with nifedipine and deflazacort
supplementation than without it. In our study, the stone-
free rate was 46.2% and 74.5% in patients who underwent
ESWL alone and ESWL plus tamsulosin treatment,
respectively (p = 0.002). For stones larger than 10 mm in
diameter, however, the success rate was significantly
greater in the patients who underwent ESWL plus tamsu-
losin treatment compared with those receiving ESWL
alone. We propose that this might be attributed to the
effect of tamsulosin in improving the passage of larger
fragments generated after ESWL. During ESWL, larger
stones often generate larger fragments that migrate less
easily. In such cases, tamsulosin could promote the pas-
sage of these fragments by increasing the intraureteral
flow and the intraureteral pressure gradient above the
stone, or by decreasing the peristalsis above the stone. As
far as expulsion time was concerned, we observed stone
passage after 11.6 days in group 1 and 8.1 days in group 2
(p < 0.001). Our results demonstrated that the use of tam-
sulosin significantly reduced expulsion times in compari-
son with the control group.
Ureteral stones usually cause severe colic pain as a
result of increasing intraureteral pressure above the site
of ureteral obstruction. The goal of treatment of ureteral
colic is to relieve the pain and release the ureteral obstruc-
tion. Experimental and clinical studies have shown that
antispasmodic drugs are effective for the relief of ureteral
colic and possibly for the promotion of stone passage, but
such drugs are generally considered unsatisfactory in
term of efficacy and safety.15 Dellabella et al1 have found
that treatment with tamsulosin provides relief of ureteral
colic pain, as indicated by significantly less analgesic 
use. In our study, ureteral colic occurred in 19.2% of
patients in group 1 but in only 5.5% of patients in group 2
(p = 0.043) demonstrating that that tamsulosin probably
worked to decrease the frequency of peristaltic contrac-
tions within the ureter.
The side effects with tamsulosin treatment after
ESWL were mild. In the study by Porpiglia et al,11 the inci-
dence of side effects with adjunctive medication was 10%,
while it was only 3.6% in our study. The rates of side
effects, such as dizziness, rhinitis and diarrhoea have been
reported to be 14.9%, 13.1% and 6.2% respectively.13 How-
ever, these rates were recorded after at least 13 weeks of
tamsulosin treatment for benign prostatic hyperplasia. 
In the present study, only 3.6% of patients (2/55) receiv-
ing tamsulosin reported slight dizziness within the 
2-week treatment period. However, this low number of
side effects was probably due to the short follow-up
period.
The results of our study demonstrate that adjunctive
therapy with α1-adrenergic antagonists following ESWL
is more effective than lithotripsy alone, while equally as
safe, for the treatment of lower ureteral stones. Our
results also indicate that α1-adrenergic antagonists are
more useful for stones with a larger diameters. Finally,
adjunctive therapy with α1-adrenergic antagonists could
significantly reduce stone expulsion time and the num-
ber of ureteral colic episodes after ESWL.
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